Share

Conclusions of IBCD 2018, the regulatory science meeting for precision medicine

The 2018 edition of the Innovation and Biomarkers in Cancer Drug Development Conference (IBCD) has gathered over 150 participants from over 15 countries and 3 continents to learn and share about the challenges of new drug development and biomarkers in cancer.

The focus of the IBCD meeting, which involved stakeholders from industry, regulatory agencies, academia and patients, was to explore the practical issues relating to how biomarker assay development could be more effectively integrated into drug development and regulatory approval processes to drive further progress in cancer-related precision medicine, all this benefiting society within a healthcare context.

IBCD offered unprecedented opportunities for cross-stakeholder discussions. Attendees and presenters repeatedly highlighted the need for dialogue-based decisions and a structured approach to biomarker development – from pre-analytical issues to routine use of biomarkers.

The meeting provided solid grounds for the evolution of clinical research towards the development of precision medicine, bringing together all stakeholders’ viewpoints on providing patients with better therapeutic options and access to innovation.

The outcomes from the conference will be published in the European Journal of Cancer and in the Clinical Cancer Research Journal.

To learn about IBCD speakers’ perspective on the conference: check their video’s interview

To watch the IBCD’s presentations: the webcasts will be available soon.

Back to news list

Related News

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival

  • New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024

  • Late Breaking Results from the EORTC 1333/PEACE III phase III trial

  • EORTC’s presence at ESMO 2024